A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
CKLSF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 6.79 Med: 9.81 Max: 19.78
Current: 19.78
During the past 13 years, the highest Debt-to-EBITDA Ratio of CK Life Sciences International Holdings was 19.78. The lowest was 6.79. And the median was 9.81.
CKLSF's Debt-to-EBITDA is ranked worse than 95.19% of 291
companies
in the Biotechnology industry
Industry Median: 1.14
vs CKLSF: 19.78
CK Life Sciences International Holdings (OTCPK:CKLSF) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
CK Life Sciences International Holdings Debt-to-EBITDA Related Terms
CK Life Sciences International Holdings Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CK Life Sciences International Holdings Debt-to-EBITDA Chart
CK Life Sciences International Holdings Annual Data
CKLSF vs VRTX, REGN, ALNY: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, CK Life Sciences International Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CK Life Sciences International Holdings Debt-to-EBITDA vs Biotechnology Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
CK Life Sciences International Holdings (CKLSF) has a Debt-to-EBITDA of 11.69 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on CK Life Sciences International Holdings. This is 19% above median its historical median of 9.81. Over the past decade, CK Life Sciences International Holdings' Debt-to-EBITDA has ranged from 6.79 to 19.78. According to the industry distribution chart, CK Life Sciences International Holdings ranks #277 out of 291 companies in the Biotechnology industry, placing it in the top 95.2%.
Is CK Life Sciences International Holdings' Debt-to-EBITDA too high?
CK Life Sciences International Holdings' current Debt-to-EBITDA of 11.69 is 19% above median its 10-year median of 9.81. Over the past 10 years, this metric has ranged from a low of 6.79 to a high of 19.78. The Biotechnology industry median Debt-to-EBITDA is 1.14. CK Life Sciences International Holdings' value of 11.69 is 925.4% above this industry median. Based on the distribution chart, CK Life Sciences International Holdings ranks #277 out of 291 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CK Life Sciences International Holdings has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does CK Life Sciences International Holdings' Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CK Life Sciences International Holdings ranks #277 out of 291 companies for Debt-to-EBITDA. This places CK Life Sciences International Holdings in the lower half of its industry. The industry median Debt-to-EBITDA is 1.14. CK Life Sciences International Holdings' value of 11.69 is 925.4% above this benchmark. Historically, CK Life Sciences International Holdings' own Debt-to-EBITDA has ranged from 6.79 to 19.78 over the past decade. While the company's 10-year median is 9.81 vs. the industry median of 1.14, CK Life Sciences International Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.14, based on 291 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CK Life Sciences International Holdings's current Debt-to-EBITDA of 11.69 is 925.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on CK Life Sciences International Holdings. For the Biotechnology industry, the median Debt-to-EBITDA is 1.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CK Life Sciences International Holdings's current Debt-to-EBITDA is 11.69, which is 19% above median its own 10-year median of 9.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CK Life Sciences International Holdings stock overvalued right now?
CK Life Sciences International Holdings (CKLSF) has a current Debt-to-EBITDA of 11.69. The stock's GF Value™ is $0.11, compared to a current price of $0.09 — trading 18.2% below its estimated fair value. The current Debt-to-EBITDA is 11.69, which is 19% above median its 10-year median of 9.81 and 925.4% above the Biotechnology industry median of 1.14. CK Life Sciences International Holdings' overall GF Score™ is 39/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For CK Life Sciences International Holdings (CKLSF), the current Debt-to-EBITDA is 11.69 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CK Life Sciences International Holdings (CKLSF) Overvalued in 2026?
Based on GuruFocus' analysis, CK Life Sciences International Holdings stock appears to be undervalued.
The current stock price of $0.09 is trading 18.2% below its estimated GF Value™ of $0.11.
Key valuation signals for CKLSF:
Debt-to-EBITDA: 11.69 (19% above median its 10-year median of 9.81)
GF Value™: $0.11 vs. price of $0.09 (18.2% below fair value)
Industry Position: 925.4% above the Biotechnology median (#277 of 291)
No single metric tells the full story. See the CKLSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CK Life Sciences International Holdings Business Description
CK Life Sciences International Holdings Inc is an international life sciences company. It is engaged in research and development, manufacturing, commercialization, marketing and selling of health and agriculture-related products, as well as investment in a portfolio of vineyards, and various financial and investment products. Its pipeline includes Seviprotimut-L, TTX-MC138, Seviprotimut-L + TTX-MC138, TTX-RIGA, Halneuron, among others. Its segments include Agriculture-related, Nutraceutical, and Pharmaceuticals & Diagnostics R&D with the majority of the revenue deriving from Nutraceutical segment. Geographically it operates in Asia Pacific that derives the majority of the revenue and North America.
39GF Score
Get the complete analysis for CKLSF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CKLSF has been successfully added to your 
